A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) prior to implantation, treating an implant formed from donor corneal tissue or a tissue culture grown corneal stroma with a solution of sodium dodecyl sulfate (SDS), Triton X-100, benzalkonium chloride (BAK), Igepal, genipin, 100% glycerol, or alcohol for making the implant acellular, and for killing any bacteria, viruses, or parasites prior to implantation; (ii) implanting the implant into a recipient cornea; (iii) applying laser energy to the implant so as to modify the refractive power of the implant while being monitored using a Shack-Hartmann wavefront system so as to achieve a desired refractive power for the implant; and (iv) applying a cross-linking solution and irradiating the implant to cross-link the implant to prevent an immune response to the implant and/or rejection of the implant by a patient.

Object of the present invention is a drug delivery system comprising a decellularized corneal stroma scaffold having dispersed within and/or bound to its surface microparticles containing at least one pharmaceutically active molecule dispersed in a matrix having a composition consisting for at least 70% of polylactic co-glycolic acid (PLGA).

The present disclosure provides an intraocular lens (IOL) or ophthalmic device including an optic and at least one haptic, at least a portion of which is formed from a photoresponsive shape memory polymer network, such as a polydomain azo liquid crystalline polymer network (PD-LCN). The present disclosure further provides systems and methods for adjusting the position of such an IOL or other ophthalmic device using polarized laser radiation.

A biomedical device is disclosed which is a polymerization product of a mixture comprising (a) one or more difunctional isocyanates; (b) one or more polyalcohols; (c) one or more hydroxy-terminated polysiloxane prepolymers; and (d) one or more polyoxazoline polyols having a weight average molecular weight of equal to or greater than about 1000 Daltons.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

The disclosure relates to a tissue adhesive for use in a treatment method in which an ophthalmological implant is implanted in a human or animal patient and the ophthalmological implant is connected, at least partially in an integrally bonded manner, to eye tissue of the patient via the tissue adhesive. The disclosure also relates to an ophthalmological implantation system including an ophthalmological implant for implantation in a human or animal eye and to a tissue adhesive via which the ophthalmological implant is connectable, at least partially in an integrally bonded manner, to eye tissue of the patient.

Described herein is a method of coating a prosthetic device, such as an ocular prosthetic device, the method comprising nanoelectrospraying droplets comprising an active ingredient and/or a carrier species onto a surface of the prosthetic device in a predetermined pattern, the nanoelectrospraying involving controlling the flow rate of the droplets from a nozzle of the nanoelectrospraying equipment by controlling the voltage between the nozzle and the ocular prosthetic device. Also described herein are ocular prosthetic device formable according to the method.

Provided herein are methods of producing a distinct bilayer culture of retinal epithelial cells (RPE) with photoreceptor cells and/or photoreceptor precursor cells (PR/PRP). Further provided herein is a therapy comprising transplantation of the RPE and PR/PRP bilayer as well as methods for testing candidate drugs using the bilayer.

A technique can consistently achieve thicknesses of ≤50 μm for corneal tissue for Descemet stripping automated endothelial keratoplasty (DSAEK). Grafts with thicknesses of ≤50 μm are also known as nanothin DSAEK (NT-DSAEK) grafts. Evidence shows that using thinner DSAEK grafts, particularly NT-DSAEK grafts, can significantly improve visual outcomes. According to an example embodiment, a method for producing a corneal graft includes drying a donor cornea to cause a pre-cut thickness of the donor cornea to decrease. The method includes, concurrently with drying the donor cornea, determining pre-cut thickness measurements for the donor cornea. The method includes, in response to the pre-cut thickness measurements indicating the pre-cut thickness of the donor cornea has decreased to a predetermined value, cutting the donor cornea to a post-cut thickness of ≤100 μm, or more particularly ≤50 μm, to produce a corneal graft.

A storage/delivery device includes a first wall defining a well configured to receive a corneal tissue. The storage/delivery device includes a second wall configured to be positioned over the first wall and to seal the well. The second wall includes a recess configured to extend into the well to define a chamber between the first wall and the second wall. The chamber is configured to hold the corneal tissue when the second wall seals the well. A system may include the storage/delivery device above and a measurement system configured to measure the corneal tissue disposed in the well. In one example embodiment, the measurement system is an optical coherence tomography (OCT) system. In another example embodiment, the measurement system is a second-harmonic generation (SHG) or third-harmonic generation (THG) microscopy system.